Details for Patent: 8,754,096
✉ Email this page to a colleague
Which drugs does patent 8,754,096 protect, and when does it expire?
Patent 8,754,096 protects QULIPTA and UBRELVY and is included in two NDAs.
This patent has sixty-four patent family members in forty-three countries.
Summary for Patent: 8,754,096
| Title: | Piperidinone carboxamide azaindane CGRP receptor antagonists |
| Abstract: | The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. |
| Inventor(s): | Bell; Ian M. (Harleysville, PA), Fraley; Mark E. (North Wales, PA), Gallicchio; Steven N. (Horsham, PA), Ginnetti; Anthony (Perkasie, PA), Mitchell; Helen J. (Richboro, PA), Paone; Daniel V. (Lansdale, PA), Staas; Donnette D. (Holland, PA), Stevenson; Heather E. (Philadelphia, PA), Wang; Cheng (Fort Washington, PA), Zartman; C. Blair (Hatfield, PA) |
| Assignee: | Merck Sharp & Dohme Corp. (Rahway, NJ) |
| Application Number: | 13/293,166 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,754,096
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | QULIPTA | atogepant | TABLET;ORAL | 215206-001 | Sep 28, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS | ⤷ Sign Up | ||
| Abbvie | QULIPTA | atogepant | TABLET;ORAL | 215206-002 | Sep 28, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS | ⤷ Sign Up | ||
| Abbvie | QULIPTA | atogepant | TABLET;ORAL | 215206-003 | Sep 28, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS | ⤷ Sign Up | ||
| Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ACUTE TREATMENT OF MIGRAINE WITH HEADACHE, WITH OR WITHOUT AURA IN ADULTS | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,754,096
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2638042 | ⤷ Sign Up | 301248 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2638042 | ⤷ Sign Up | PA2023532 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2638042 | ⤷ Sign Up | CR 2023 00033 | Denmark | ⤷ Sign Up |
| European Patent Office | 2638042 | ⤷ Sign Up | 2023C/541 | Belgium | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
